Revance Therapeutics (NASDAQ:RVNC – Free Report) had its price target decreased by Needham & Company LLC from $44.00 to $40.00 in a research report report published on Wednesday, MarketBeat.com reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented […]
Integral Health Asset Management LLC boosted its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 4.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 250,000 shares of the biopharmaceutical company’s stock after buying an additional 10,000 shares during the period. […]
Revance Therapeutics (NASDAQ:RVNC – Free Report) had its price target trimmed by HC Wainwright from $48.00 to $41.00 in a report issued on Wednesday, Marketbeat reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Revance Therapeutics’ Q3 2023 earnings at ($1.05) EPS, Q4 2023 earnings […]
Revance Therapeutics (NASDAQ:RVNC – Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08), Briefing.com reports. Revance Therapeutics had a negative net margin of 224.65% and a negative return on equity of 1,091.00%. The company had […]
Revance Therapeutics (NASDAQ:RVNC – Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08), Briefing.com reports. Revance Therapeutics had a negative net margin of 224.65% and a negative return on equity of 1,091.00%. The company had revenue […]